Notifications
Back

Exploring the frontier of pharmaceutical innovation


Daewoong Therapeutics R&D

Research & Development

Discover Daewoong Therapeutics’ stable and differentiated business model 

We pursue the research and development of microneedle platforms, innovative drugs, ocular drug delivery systems and innovative veterinary medicines – all aimed at improving the quality of life for both humans and animals.
Our model ensures a sustainable R&D cycle by generating steady cash flow through the development of value-added drugs and acquisition of royalty income. 

Platform Technology  

 

In-house pipeline through advanced DDS platform technology & DDS-driven new drug development strategy 

 

  • Microneedle Patch
    - Transdermal delivery of macromolecules
    - Cosmetics
    - Therapeutics and vaccines
    - GLP-1 analogue, botulinum toxin, growth hormone
  • Microparticle
    - Cosmetics

Innovative DDS-based Therapeutics addressing Unmet Needs  

 

 

  • Nano-micelle eyedrop
    - Eyedrop for diabetic retinopathy (DR)/diabetic macular edema (DME)
  • Incrementally Modified Drugs (IMD)
  • Combination drug

Formulation CRO/CDO Services 

 

Cash cow 

 

  • Development of high-demand, high-potential products
  • Securing short-term milestone payments
  • Generating long-term royalty income
  • Contract and joint research with domestic pharmaceutical companies
  • Technology transfer

Veterinary Medicines 

 

Open collaboration 

 

  • Application of advanced drug delivery platform technologies
  • Development of formulations for higher compliance addressing major unmet needs in veterinary medicine
  • Development and manufacturing of spot-on, implants, and specialized feeds
  • Long-acting implants and customized therapeutics for animals
  • Microneedle patches for veterinary use